Cargando…

Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B

Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle–formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elici...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jun, Budylowski, Patrick, Samson, Reuben, Griffin, Bryan D., Babuadze, Giorgi, Rathod, Bhavisha, Colwill, Karen, Abioye, Jumai A., Schwartz, Jordan A., Law, Ryan, Yip, Lily, Ahn, Sang Kyun, Chau, Serena, Naghibosadat, Maedeh, Arita, Yuko, Hu, Queenie, Yue, Feng Yun, Banerjee, Arinjay, Hardy, W. Rod, Mossman, Karen, Mubareka, Samira, Kozak, Robert A., Pollanen, Michael S., Martin Orozco, Natalia, Gingras, Anne-Claude, Marcusson, Eric G., Ostrowski, Mario A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769538/
https://www.ncbi.nlm.nih.gov/pubmed/35044832
http://dx.doi.org/10.1126/sciadv.abj9815
_version_ 1784635166914772992
author Liu, Jun
Budylowski, Patrick
Samson, Reuben
Griffin, Bryan D.
Babuadze, Giorgi
Rathod, Bhavisha
Colwill, Karen
Abioye, Jumai A.
Schwartz, Jordan A.
Law, Ryan
Yip, Lily
Ahn, Sang Kyun
Chau, Serena
Naghibosadat, Maedeh
Arita, Yuko
Hu, Queenie
Yue, Feng Yun
Banerjee, Arinjay
Hardy, W. Rod
Mossman, Karen
Mubareka, Samira
Kozak, Robert A.
Pollanen, Michael S.
Martin Orozco, Natalia
Gingras, Anne-Claude
Marcusson, Eric G.
Ostrowski, Mario A.
author_facet Liu, Jun
Budylowski, Patrick
Samson, Reuben
Griffin, Bryan D.
Babuadze, Giorgi
Rathod, Bhavisha
Colwill, Karen
Abioye, Jumai A.
Schwartz, Jordan A.
Law, Ryan
Yip, Lily
Ahn, Sang Kyun
Chau, Serena
Naghibosadat, Maedeh
Arita, Yuko
Hu, Queenie
Yue, Feng Yun
Banerjee, Arinjay
Hardy, W. Rod
Mossman, Karen
Mubareka, Samira
Kozak, Robert A.
Pollanen, Michael S.
Martin Orozco, Natalia
Gingras, Anne-Claude
Marcusson, Eric G.
Ostrowski, Mario A.
author_sort Liu, Jun
collection PubMed
description Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle–formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust humoral and cellular immune responses and completely protected the vaccinated animals from SARS-CoV-2 infection in the lung. Studies in hamsters also showed that PTX-COVID19-B protected the upper respiratory tract from SARS-CoV-2 infection. Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages. No adverse effects were induced by PTX-COVID19-B in either mice or hamsters. Based on these results, PTX-COVID19-B was authorized by Health Canada to enter clinical trials in December 2020 with a phase 2 clinical trial ongoing.
format Online
Article
Text
id pubmed-8769538
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-87695382022-02-01 Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B Liu, Jun Budylowski, Patrick Samson, Reuben Griffin, Bryan D. Babuadze, Giorgi Rathod, Bhavisha Colwill, Karen Abioye, Jumai A. Schwartz, Jordan A. Law, Ryan Yip, Lily Ahn, Sang Kyun Chau, Serena Naghibosadat, Maedeh Arita, Yuko Hu, Queenie Yue, Feng Yun Banerjee, Arinjay Hardy, W. Rod Mossman, Karen Mubareka, Samira Kozak, Robert A. Pollanen, Michael S. Martin Orozco, Natalia Gingras, Anne-Claude Marcusson, Eric G. Ostrowski, Mario A. Sci Adv Biomedicine and Life Sciences Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle–formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust humoral and cellular immune responses and completely protected the vaccinated animals from SARS-CoV-2 infection in the lung. Studies in hamsters also showed that PTX-COVID19-B protected the upper respiratory tract from SARS-CoV-2 infection. Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages. No adverse effects were induced by PTX-COVID19-B in either mice or hamsters. Based on these results, PTX-COVID19-B was authorized by Health Canada to enter clinical trials in December 2020 with a phase 2 clinical trial ongoing. American Association for the Advancement of Science 2022-01-19 /pmc/articles/PMC8769538/ /pubmed/35044832 http://dx.doi.org/10.1126/sciadv.abj9815 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Biomedicine and Life Sciences
Liu, Jun
Budylowski, Patrick
Samson, Reuben
Griffin, Bryan D.
Babuadze, Giorgi
Rathod, Bhavisha
Colwill, Karen
Abioye, Jumai A.
Schwartz, Jordan A.
Law, Ryan
Yip, Lily
Ahn, Sang Kyun
Chau, Serena
Naghibosadat, Maedeh
Arita, Yuko
Hu, Queenie
Yue, Feng Yun
Banerjee, Arinjay
Hardy, W. Rod
Mossman, Karen
Mubareka, Samira
Kozak, Robert A.
Pollanen, Michael S.
Martin Orozco, Natalia
Gingras, Anne-Claude
Marcusson, Eric G.
Ostrowski, Mario A.
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
title Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
title_full Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
title_fullStr Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
title_full_unstemmed Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
title_short Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
title_sort preclinical evaluation of a sars-cov-2 mrna vaccine ptx-covid19-b
topic Biomedicine and Life Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769538/
https://www.ncbi.nlm.nih.gov/pubmed/35044832
http://dx.doi.org/10.1126/sciadv.abj9815
work_keys_str_mv AT liujun preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT budylowskipatrick preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT samsonreuben preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT griffinbryand preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT babuadzegiorgi preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT rathodbhavisha preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT colwillkaren preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT abioyejumaia preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT schwartzjordana preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT lawryan preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT yiplily preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT ahnsangkyun preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT chauserena preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT naghibosadatmaedeh preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT aritayuko preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT huqueenie preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT yuefengyun preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT banerjeearinjay preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT hardywrod preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT mossmankaren preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT mubarekasamira preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT kozakroberta preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT pollanenmichaels preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT martinorozconatalia preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT gingrasanneclaude preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT marcussonericg preclinicalevaluationofasarscov2mrnavaccineptxcovid19b
AT ostrowskimarioa preclinicalevaluationofasarscov2mrnavaccineptxcovid19b